- Home
- OTLK vs OABI Comparison
OTLK vs OABI Comparison
Compare OTLK & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OTLK | OABI |
|---|---|---|
| Founded | 2010 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.6M | 294.3M |
| IPO Year | 2016 | 2021 |
Fundamental Metrics
Financial Performance| Metric | OTLK | OABI |
|---|---|---|
| Price | $0.64 | $4.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $2.50 | ★ $4.50 |
| AVG Volume (30 Days) | ★ 21.3M | 1.7M |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.91 | 6.56 |
| EPS | N/A | ★ N/A |
| Revenue | $8,146,123.00 | ★ $18,666,000.00 |
| Revenue This Year | $1,430.98 | $52.42 |
| Revenue Next Year | $173.23 | $64.69 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.16 | $1.32 |
| 52 Week High | $2.54 | $4.93 |
Technical Indicators
Market Signals| Indicator | OTLK | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 32.63 | 76.67 |
| Support Level | $0.19 | $1.65 |
| Resistance Level | $0.94 | N/A |
| Average True Range (ATR) | 0.07 | 0.31 |
| MACD | -0.01 | 0.08 |
| Stochastic Oscillator | 8.15 | 74.31 |
Price Performance
Historical ComparisonAbout OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About OABI OmniAb Inc.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.